Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

This study is testing a new drug called WEF-001 in adults with advanced solid tumors that have a specific genetic mutation called KRAS. KRAS mutations are common in several hard-to-treat cancers, and this drug is designed to target that mutation. **You may be eligible if...** - You are an adult with a KRAS-mutant advanced solid tumor — including pancreatic cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, cholangiocarcinoma, or bladder cancer - Your cancer has progressed after at least one standard treatment - You have at least one measurable tumor - You are in good physical condition (ECOG 0 or 1) **You may NOT be eligible if...** - You have an active serious infection - You have active heart disease or significant liver problems - You have untreated brain metastases - You have inflammatory bowel disease, lupus, or active uncontrolled thyroid disease Talk to your doctor to see if this trial is right for you.